Back

Opko Health Inc

Ticker: OPK ISIN: US68375N1037
Add to portfolio Portfolio analysis in 2min
Stock Small-cap High beta
Market cap
$1.09B
Forward P/E
64.52
Profit margin
-5.66%
Revenue growth QoQ
-13.70%
Beta
1.37
$1.49 0.68%
Price as of 2026-08-25 · NASDAQ

Performance by timeframe

Rolling returns
1 Month +20.16%
6 Months +29.57%
1 Year +7.19%
5 Years -17.00% p.a.-60.58%
10 Years -16.73% p.a.-83.94%
Since inception -3.36% p.a.-57.43%
Calendar year returns
YTD +18.25%
2025 -14.29%
2024 -2.65%
2023 +20.80%
2022 -74.01%
2021 +21.77%

Key stats

Market cap
1.09B
Beta
1.37
52-week range
1.19 - 2.04
50-day MA
1.41
200-day MA
1.54
Section 1

Business overview

Company profile data from fundamentals.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.

Sector Healthcare
Industry Diagnostics & Research
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -3.04%
ROA -8.20%
Profit margin -5.66%
Operating margin -44.79%
PEG ratio -2.87
Revenue/share TTM 1.01
Revenue TTM 689.41M
EBITDA -173.41M
Gross profit TTM 104.94M
Beta 1.37

Valuation

Trailing P/E 0.00
Forward P/E 64.52
P/B 0.83
P/S 1.58
EV/EBITDA 7.62
EV/Revenue 1.66
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -0.37
Quarterly earnings growth 19.10%
Revenue TTM 689.41M
Reported quarters 107
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $3.99
Analyst rating 4.1429

Ownership & short interest

Shares outstanding 793.05M
Shares float 375.14M
Institutional ownership 31.11%
Insider ownership 46.81%
Short ratio 9.85
Short % of float 7.32%

Details

Instrument metadata and source update timestamps.

Symbol OPK
Name Opko Health Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US68375N1037
Country USA
Code + exchange OPK.NASDAQ
Fundamentals updated 2025-06-06

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.